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Although the mechanisms by which the nervous system can influence immune 
responses are poorly understood, the concept that certain neuropeptides may 
regulate immunological responses through direct effects on lymphoid cells has 
been suggested by in  vitro investigations from a  number of laboratories.  For 
example, beta-endorphin has been found to  modulate mitogen responses (1), 
immunoglobulin synthesis (2), and spontaneous cytotoxicity expression by human 
peripheral blood mononuclear cells (3).  Receptors for beta-endorphin have also 
been demonstrated on human lymphoid cells (4).  Another neuropeptide, neu- 
rotensin, has been shown to bind to and modulate the phagocytic behavior of 
mouse peritoneal macrophages (5),  and a  partially homologous neuropeptide, 
substance P, has been shown to stimulate human T  lymphocyte proliferation (6). 
An immunoregulatory role has also been suggested for vasoactive intestinal 
peptide (VIP). 1 VIP is a 28-amino acid neuropeptide that is found within neurons 
of the central and peripheral nervous system (7-9).  VIP-containing nerves are 
abundant in the vagus and splanchnic nerves (10, 11) and in mucosal tissues such 
as the gastrointestinal and upper respiratory tracts, salivary glands, and the male 
and female genital tracts (12,  13).  Human peripheral blood mononuclear cells 
(14,  15),  human  peripheral  blood  T  cells (16),  and a  human  T  cell-derived 
culture line (Molt 4b) (17) have all been demonstrated to possess specific binding 
sites for VIP. Specific receptors for VIP have also been demonstrated on mouse 
T  cells (18) and in the presence of VIP a  dose-dependent inhibition of the in 
vitro response of mouse lymphocytes to T  cell mitogens has been found (18). 
It has been proposed that a  prime means through which neurophysiological 
factors might influence the immune system is by regulation of the migration of 
lymphocytes through  lymphoid  tissue  (19).  The  object  of the  investigations 
reported here was to test the hypothesis that receptors for VIP on mouse T  cells 
contribute to their migratory properties. Because there is, at present, no known 
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way in which to selectively disrupt VIP-containing nerves in vivo, the strategy 
chosen in the present studies was to perturb the expression of VIP receptors on 
T  cells and to examine the effect of this perturbation on the subsequent migration 
of T  cells in vivo. 
It  is  well  established  that  the  interaction  of target  cells  with a  number  of 
hormone and neurotransmitter ligands can alter the receptor characteristics of 
the target cells (20). This can occur in at least two ways. First, receptor occupancy 
over short periods of time may modify the behavior of unoccupied receptors for 
the  ligand.  Such  cooperativeness  between  receptors  is  unlikely with  the  VIP 
receptors  of mouse T  cells,  because  the  dissociation of labeled  VIP  has  been 
found to be independent of the concentration of VIP available to the lymphocytes 
(18). A second mechanism can occur in a number of target cells (20-26), whereby 
binding capacity for a  ligand and the subsequent response of cells to the ligand 
can be modified by more prolonged ligand exposure of the cells. 
The results obtained in the present studies show that in vitro incubation of T 
cells in the presence of VIP leads to dose-dependent alterations in the expression 
of VIP receptors and changes in the ability of the treated T  cells to localize in 
mesenteric node and Peyer's patch lymphoid tissues of recipient animals. 
Materials and Methods 
Mice.  Female BALB/c mice 6-8 wk of age were purchased from Canadian Breeding 
Laboratories (Montreal, P.Q.). 
Vasoaetive Intestinal  Peptide.  Synthetic porcine  VIP  was  purchased from Peninsula 
Laboratories (San Carlos, CA).  Radioiodinated VIP was prepared from native porcine 
VIP by the lactoperoxidase method and repurified by ion-exchange chromatography as 
previously described (I 5). 
Cell Suspensions.  Single cell suspensions of lymphocytes from mesenteric lymph nodes 
(MLN) were prepared at room temperature by gentle teasing of the tissues in RPMI 1640 
medium (Gibco Canada Ltd., Burlington, Ontario) containing 5% fetal calf serum (FCS; 
Gihco). The cell suspensions were filtered through a 2-cm column of glass wool to remove 
debris, and the number of viable cells in suspension was determined by their ability to 
exclude 0.2%  eosin.  Cell suspensions were enriched for T  cells  by using nylon wool 
columns according to the method of  Julius et ai. (27). 
Cell Incubation.  Cells to be  used in incubations were washed three times in RPMI 
1640 and resuspended at 2 ×  106 cells/ml in RPMI 1640 supplemented with 10% FCS, 
penicillin (100 U/ml, Gibco), streptomycin (100 ug/ml, Gibco), 4 mM L-glutamine (Sigma 
Chemical Co., St.  Louis, MO),  1 mM sodium pyruvate (Gibco), and 1 mM nonessential 
amino acids (Gibco). Cells were incubated in 25-cm  ~ flasks (Falcon 3013; Falcon Plastics 
Co., Oxnard, CA) at 37°C in an atmosphere of 5% CO2. 
Binding Studies.  Binding studies were carried out using 7.5 ×  10  -H M labeled VIP in 
the presence or absence of unlabeled VIP in binding medium consisting of RPMI 1640 
containing 5% bovine serum albumin (BSA; Sigma) as previously described (18). Briefly, 
cells for the binding assay were washed three times in RPMI 1640 at 37 °C, resuspended 
in the binding medium at 5 ×  106 cells/ml, and then incubated with radiolabeled VIP for 
60 min at room temperature. Cell-associated,  labeled peptide was separated by centrif- 
ugation at 6,500 g for 1 min and then washed three times with binding medium at 4°C 
to remove unbound label, and the radioactivity of the cell sediments and supernatants 
was determined. Specific  binding was measured as the difference between cell-bound 
radioactivity found in the absence and presence of 10  -7 M unlabeled VIP as a competitor 
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Complement-mediated Cytotoxicity.  Cells to be used in cytotoxicity assays were washed 
three times in  RPMI  1640 at  37°C and resuspended  in  RPMI  1640 containing 0.3% 
BSA. M0noclonal anti-Thy-l.2 and anti--Lyt-2.2 antibodies were purchased from New 
England Nuclear Corp. (LaChine P.Q.) Monoclonal anti-Lyt-l.2 antibody was purchased 
from Cedarlane  Laboratories (Hornby, Ontario). These were used in cytotoxicity assays 
at final  dilutions of 1/200,  1/1,600,  and  1130, respectively, for 2.5 ×  106 cells/0.5 mi. 
These dilutions were found to be maximally effective in producing cytotoxicity of thymus 
cells from these animals.  Cytotoxicity was developed in the presence of low toxicity rabbit 
complement (C) (Cedarlane Laboratories) at a final dilution of 1/10. 
Localization Studies.  Cells to be used for in vivo localization were washed three times 
with  RPMI  1640  at  37°C and  resuspended  in  RPMI  1640  containing  5%  FCS.  Cell 
labeling was carried out by incubation with (S'Cr) sodium chromate (New England Nuclear) 
at 50 #Ci/10  s cells/ml at 37°C for 30 min. The labeled cells were washed three times in 
RPMI 1640 without FCS and injection doses of 5 ×  106 labeled cells were given through 
a lateral tail vein in 0.4-ml volumes. Multiple samples of each injection dose were kept for 
counting of the administered radioactivity. At intervals after cell transfer, recipient mice 
were killed by cervical dislocation and the abdomen immediately opened. The aorta and 
vena cava were cut and  a  measured  volume of blood collected.  Mesenteric  node and 
Peyer's patches lymphoid tissues of the recipients were dissected and immediately weighed 
in tared containers. The in vivo localization of labeled lymphocytes was expressed as the 
percentage of the injected dose of radioactivity found per gram of tissue, per milliliter  of 
blood or per organ. 
Analysis of Data.  Results were expressed as the mean -+ standard deviation for replicas 
of experiments or groups of animals and compared by Student's t test.  Tracer dilution 
studies  of ~sI-VIP binding were assessed by Scatchard anlaysis (29). 
Results 
Alteration of VIP Receptors with Incubation 
When T-enriched populations of mesenteric node lymphocytes were incubated 
in the presence of 10  -7 M  VIP, there was a  decrease in the ability of the cells to 
specifically bind 125I-labeled VIP (Table I). Alteration in specific binding of VIP 
to the cells was time dependent, and was well developed by 18 h  of incubation 
(Table I). This alteration of VIP binding was investigated by studying the binding 
properties of T-enriched populations that had been incubated in the presence or 
absence of 10 -7 M  VIP for 18 h. Suspensions of cells incubated in the presence 
TABLE  I 
Effect of Incubation with VIP on the Specific Binding of VIP to 
T-Enriched Lymphocytes* 
Time of incubation  Specific VIP binding (% control) 
h 
3  61.6 ___ 5.5 
6  42.1 _ 5.8 
18  33.4 :t= 5.2 
42  27.7 ___ 7.5 
* Nylon wool effluent MLN cells were incubated for the times shown in 
the presence or absence (control cells) of 10  -7 M VIP. The cells were 
harvested and washed and the specific binding of ~I-VIP was deter- 
mined. The results are the means + SD of three experiments. OTTAWAY  1057 
of 10 -7 M VIP bound much less VIP throughout a  wide range of VIP concen- 
trations than did cells incubated without the addition of VIP (Fig.  1). Scatchard 
analyses (Table II) of these tracer dilution experiments suggested that there was 
a marked alteration in the density of VIP binding sites in these two types of cell 
suspensions, but there was no significant alteration of the affinity of the cells for 
VIP. 
When  T-enriched  populations  of  MLN  lymphocytes  were  incubated  with 
different  concentrations  of VIP,  there  was a  dose-dependent  decrease  in  the 
ability of the incubated cells to specifically bind ]~SI-VIP (Fig. 2). 
Thus, in vitro exposure of T  cells to VIP induces a time-dependent and dose- 
dependent  down  regulation  of the  expression  of VIP  receptor  sites  on  the 
incubated lymphocytes. 
Phenotypes of Incubated Lymphocyte Populations.  The  expression  of T  cell- 
associated surface markers by the incubated cell populations was examined (Table 
0  x  10  "!°  2  10  "1°  4  x  10  "1°  6  x  10  "~°  7.5 x  10  "~°  1 x  10" 
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FIGURE  1.  Binding of VIP to T-enriched populations of MLN lymphocytes incubated with 
or without VIP.  Nylon wool effluent cells were incubated for  18 h  in the presence (hatched 
areas) or absence (open areas) of 10  -~ M VIP, harvested, washed, and incubated with I~sI-VIP 
in the presence of different concentrations of unlabeled VIP for 60 rain at 22°C,  and the 
percent of the added t~5I-VIP specifically bound to the cells was determined. The results are 
the means (± SD) of triplicate determinations from four experiments with each type of cell 
suspension. 
TABLE  II 
VIP Binding Characteristics of T-Enriched  Lymphocytes Incubated 
with or without VIP* 
Incubation  KD (10  -I° M)  Sites/cell 
No VIP  2.6 ±  0.7  5,200 ±  970 
10  -~ M VIP  3.5 ±  1.5  2,810 ±  520 
* Results  are  the  means  ±  SD  for  the  parameters  determined  from 
Scatchard analyses of four independent experiments with each type of 
cell suspension. Nylon wool effluent MLN cells were incubated for 18 h 
in the concentration of VIP shown. 1058  VIP  RECEPTORS  AND  THE  IN  VIVO  LOCALIZATION  OF  T  CELLS 
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FIGURE 2.  Specific binding of 1251-VlP to  T-enriched MEN  lymphocytes incubated with 
different concentrations of VIP.  Nylon wool effluent cells were incubated for  18  h  in the 
absence of VIP (hatched area) or in the presence of the concentrations of VIP shown (open 
areas).  The cell suspensions were harvested, washed, and the specific binding of VIP was 
assessed. The results are the means (_+ SD) of triplicate determinations  from three experiments 
with each condition. 
TABLE  III 
Surface Markers of T-Enriched Lymphocytes Incubated with or 
without VIP* 
Percent of cells killed: 
Antiserum  incubation 
-VIP  +VIP 
Anti-Thy-l.2  93.5 +  2.5  94.8 _+ 4.3 
Anti-Lyt-l.2  83.5 _+ 4.1  84.7 _  2.6 
Anti-Lyt-2.2  10.2  4- 3.2  11.5 +  3.7 
* Nylon wool effluent MLN cells were incubated for 18 h in the presence 
or absence of 10 -? M VIP, harvested, washed, and tested in C-mediated 
cytotoxicity assays for the markers shown. The results are the means _+ 
SD for four experiments. 
III).  There was no difference in  the proportion of cells which were killed by 
Thy-l.2,  Lyt-l.2, or Lyt-2.2  monoclonal antisera plus C  in suspensions which 
had been incubated in the presence or absence of 10 -7 M VIP. Therefore, the 
decreased density of VIP receptors expressed by the cell suspensions preincu- 
bated  in  the  presence of the  peptide  is  not  accompanied by  changes  in  the OTTAWAY  1059 
expression of these major structural  determinants  of the T  cells in the suspen- 
sions. 
In Vivo Localization  of  Incubated  T-enriched Populations.  To examine the effect 
that in vitro-induced alterations in VIP receptor expression may have on the in 
vivo localization  of the  cells,  populations  of mesenteric  node T  cells that  had 
been incubated for 18 h in the presence or absence of 10  -7 M VIP were labeled 
with ~lCr and  injected  into recipient  animals.  When  the organ distribution  of 
these labeled cell populations  was assessed  1 h  after cell  transfer,  there  was a 
marked decrease in the recovery of VIP-pretreated cells in the mesenteric lymph 
node (MLN) and  Peyer's patches of the recipient animals (Fig.  3).  In contrast, 
there was no difference in the availability of VIP-treated or untreated incubated 
cells in the blood of the recipients and there was no difference in the recovery 
of these different cell populations in other major organs of the recipients (Table 
IV). 
At 18 h after cell transfer,  the recovery of injected ceils in the blood, spleen, 
liver, and lungs was less than that found at 1 h after cell transfer (Table V), while 
further accumulation of the injected radioactivity had occurred in the mesenteric 
nodes  and  Peyer's  patches  (Table  V).  There  was  no  longer  any  significant 
difference,  however,  in  the  accumulation  of the  differently treated  incubated 
cells in any of the tissues examined (p >  0.05) (Table V). 
When  populations  of MLN  T  cells  that  had  been  incubated  with  varying 
concentrations of VIP were labeled and transferred, the 1 h localization of those 
cells in mesenteric node and Peyer' patches was decreased in a  dose-dependent 
manner  (Fig.  4),  but  there  was  no  alteration  in  the  way in  which  these  cell 
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FIGURE 3.  Localization  1 h  after cell transfer of T-enriched MLN  lymphocytes incubated 
with or  without VIP.  Nylon  wool  effluent cells were  incubated for  18  h  in  the presence 
(hatched areas) or absence (open areas) of I0  -~ M  VIP, harvested, washed, and labeled with 
S=Cr and transferred to recipients. The results are the means (_+ SD) for four or five animals 
in each group for the localization in mesenteric nodes (MLN) and Peyer's patches (PP) in three 
experiments. *P <  0.05 for comparison between cells incubated in the presence or absence of 
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TABLE  IV 
Tissue Distribution  I  h after Cell Transfer of T-Enriched  Lymphocytes Incubated  with or 
without  VIP* 
Treatment  Experiment 
Tissue  (+) VIP  1  2  3 
Blood/ml  -  1.7 2  0.2  1,4 2  0.1  1.5 4- 0.5 
+  1.6 4- 0.9  1.1  2  0.1  1.4 2  0.2 
Spleen  -  29.2 2  4.4  35,2 2  2.8  32.6 2  1.2 
+  28.1  2  3.5  34.9 4- 2.9  34.2 2  3.6 
Liver  -  14.5 ±  1.5  11,0 2  0.5  12.5 4- 0.3 
+  15.0 2  1.6  10.1  4- 0.2  14.9 2  2.0 
Lung  -  7.32  1.2  7.1  ±  1.1  6.7+0,9 
+  10.7 4-  1.2  6.1  2  1.1  7.4 4-  1.8 
Small intestine  -  1.6 2  0.5  0.9 2  0.2  1.5 2  0.2 
+  1.7 ±  0.7  1.2 _4- 0.4  1.5 4- 0.5 
Large intestine  -  2.6 4- 0.7  1.5 4- 0.3  2,3 2  0.4 
+  2.6 4- 0.7  1.2 2  0.5  2.2 ±  0.7 
* Nylon wool effluent MLN cells were incubated for 18 h in the presence or absence of 10 -7 M VIP, 
harvested, washed, and labeled with S~Cr and transferred to recipients. Results are the means 2  SD 
of the percentage of the injected dose per milliliter (blood) or the percentage of the injected dose 
per organ for four or five animals in each group. The small intestine excludes Peyer's patches; the 
large intestine includes cecum. 
TABLE  V 
Tissue Distribution  18 h after Cell Transfer of T-Enriched  Lymphocytes Incubated with or 
without  VIP* 
Tissue 
Treat- 
ment 
(2) VIP 
Experiment 
1  2  3 
BIood/ml  -  0.8 2  0.4  0.6 2  0.2  0.9 2  0.2 
+  0.4 +  0.2  0.6 +  0.2  1.2 +  0.4 
Mesenteric node/g  -  191.3  2  32.7  244.7  4- 55,7  264.0 4- 20.4 
+  164.1  2  27.0  217.5 2  28.2  241.5 2  32.5 
Peyer's patch/g  -  62.1  +  6.7  77.1  __. 4.3  78.5 4- 5.3 
+  55.1  26.3  59.4 +  13.6  59.7 2  11.1 
Spleen  -  21.8 2  2.1  24.1  __-  1.3  23.0 ±  1.7 
+  22.9 2  1.1  22.3 2  2.5  23.2 2  1.4 
Liver  -  9.9 2  1.2  7.6 2  0.4  8.1  4- 0.6 
+  11.0 2  1.1  8.5 2  0.9  9.6 2  1.0 
Lung  -  1.5  4- 0.5  1.3 --- 0.2  1.9 4- 0.4 
+  1.9 +  0.4  1.8 +  0.4  2.1  4- 0.8 
Small intestine  -  1.3  +  0.7  0.7 +  0.2  1.6 ±  0.2 
+  1.2 ±  0.4  0.9 _  0.4  1.4 +  0.5 
Large intestine  -  2.9 2  0.5  1.8 4- 0.9  2.9 2  0.7 
+  2.5 +  0.6  1.7 4- 0.4  3.6 2  0.6 
* Nylon wool effluent MLN cells were incubated for 18 h in the presence or absence of 10 -7 M VIP, 
harvested, washed, and labeled with 51Cr and transferred to recipients. The results are the means 
±  SD of the percentage of the injected dose per milliliter (blood), the percentage of the injected 
dose per gram for mesenteric node and Peyer's patches, or the percentage of the injected dose per 
organ for four or five animals in  each  group. The small intestine excludes  Peyer's patches,  the 
large intestine includes the cecum. OTTAWAY  1061 
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FIGURE 4.  Localization I h after cell transfer of T-enriched MLN lymphocytes incubated in 
the presence of different concentrations of VIP. Nylon wool effluent cells were incubated for 
18 h  in the absence (hatched areas) of VIP or in the presence of the concentrations of VIP 
indicated (open areas). The incubated cells were harvested, washed, labeled, and transferred 
to  recipients, and then their distribution in different organs assessed.  The  results are the 
means (+ SD) for three to four animals in each group. 
populations localized in the spleen and small intestine (Fig. 4). Preincubation of 
the cells in different concentrations  of VIP also did not affect the amounts of 
ceil-associated radioactivity available in the blood or recovered from other major 
organs of these recipients (data not shown). 
In other experiments, the early time course of the distribution of T-enriched 
populations that had been incubated for 18 h in the presence or absence of 10  -7 
M VIP was examined (Fig. 5). Although there was a rapid decline in the amounts 
of injected radioactivity recovered from the blood of the recipients, the availa- 
bility  of blood-borne  label  with  the  differently  treated  cell  populations  was 
equivalent (Fig.  5). The accumulation of injected radioactivity in the spleens of 
the recipients was also similar with both groups of treated cell populations, but 
there  was  a  marked  difference  in  the  rate  at  which  the  VIP-pretreated  cells 1062  VIP  RECEPTORS  AND  THE  IN  VIVO  LOCALIZATION  OF  T  CELLS 
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FIGURE 5.  Early time course of the tissue accumulation of T-enriched MLN lymphocytes 
incubated with or without VIP. Nylon wool effluent cells were incubated for  18  h  in the 
absence (open areas) or presence (hatched areas) of 10 -7 M VIP, harvested, washed, labeled, 
and transferred to recipients, and their distribution assessed at the times indicated after cell 
transfer. The results are the means (_+ SD) for three to four animals per group. 
accumulated in the mesenteric nodes and Peyer's patches of the recipients (Fig. 
~). 
Thus, preincubation of T  cells with the peptide VIP leads to a reduced ability 
of the cells to migrate, at early times after cell transfer, into the mesenteric node 
and Peyer's patches of recipient animals. 
Discussion 
The purpose of this study was to examine the hypothesis that receptors for 
VIP affect the in vivo migration of T  cells. The experiments demonstrate that 
incubation of suspensions of T  cells in the presence of VIP results in a concom- 
itant  decrease in  the  binding  capacity of the  incubated  cells  for  VIP  and  a 
selective decrease in  the early in  vivo  localization of the  treated cells in  the 
mesenteric nodes and Peyer's patches of syngeneic recipients. 
It is important that the altered localization of the VIP-treated cell populations 
was not associated with changes in the expression of Thy-1 or Lyt markers by 
the cells (Table III) because not only are T  and B cells known to differ in their 
migratory properties (30), but it has been shown that subpopulations of T  cells 
defined on the basis of Lyt- 1 (31) and Lyt-2 (32) surface markers show differences 
in migration. 
The altered localization of VIP-pretreated cells in the mesenteric node and 
Peyer's patches at early times after cell transfer is consistent with the notion that OTTAWAY  1063 
cellular receptors for VIP contribute to events controlling the entry of T  cells 
into these tissues.  The principal  factors that appear to influence the entry of 
lymphoid cells into tissues are the concentration of cells in the blood stream, the 
delivery of blood flow to the tissues, and the interaction of the cells with the 
vascular endothelium (33-35). 
In  these  experiments,  there  was  no  difference in  the  availability  of VIP- 
pretreated or control cells in the blood of the recipients (Tables IV and V, Fig. 
5).  and there was no apparent difference in the way in  which the differently 
treated cells were retained by organs such as the lungs and the liver (Tables IV 
and V). Thus, variations in the presence of the differently treated cell populations 
in the blood stream cannot account for the observed differences in their localiza- 
tion. 
VIP acquired its name because it has vasodilatory properties (36). Even though 
the incubated cell populations were carefully washed at 37°C under conditions 
that lead to the rapid dissociation of ceil-bound VIP (18), it is conceivable that 
the VIP-pretreated cells might contain small amounts of intracellular peptide 
that could produce hemodynamic changes in the recipient animals. In this regard, 
it has been postulated that receptor-mediated ligand internalization plays a critical 
role in the down regulation of surface receptors of a variety of target cells (22- 
26), but it is not known whether such internalization is necessary for, or indeed 
plays any role in this process (21).  It is unlikely, however, that the localization 
changes observed here are due to  hemodynamic alterations secondary to  the 
transfer of peptide by such means because a number of studies have shown that 
it requires the infusion of large amounts of VIP to produce transient increases 
in the flow of blood in the splanchnic vasculature of experimental animals (36, 
37) or a redistribution of intestinal blood flow in rodents (38). Furthermore, if 
increased blood flow occurred to tissues served by these vessels,  then increased, 
rather than decreased, localization of cells would be expected in  the affected 
tissues (33, 39). 
Thus,  it  is  likely that  the induced changes in  migration  of the  differently 
treated cells reflect alterations in  the way in which the cells interact with the 
vascular endothelium of MLN and Peyer's patches. The specialized high endo- 
thelium of the postcapillary venules (HEV) of lymph nodes and Peyer's patches 
is recognized as the site through which lymphocytes leave the blood to enter 
these tissues (40, 41). Numerous investigations of both the in vitro adherence of 
lymphocytes to these endothelial structures and the in vivo migration of lympho- 
cytes (42-44)  have suggested  that  the  interaction of HEV  with  specific cell- 
surface components of lymphocytes mediates their migration into these lymphoid 
organs. 
The molecular basis for the interaction of lymphocytes with HEV is not yet 
fully understood, but it has been shown that a factor isolatable from rat thoracic 
duct lymph can inhibit the binding of lymp.hocytes to lymph node HEV in vitro 
(45,  46).  Furthermore, an antiserum against this inhibitory factor binds to rat 
thoracic duct lymphocytes, and  treatment of lymphocytes with  F(ab)2  or  Fab 
fragments of the antiserum selectively decreased the in vivo accumulation of B 
and T  cells in lymph nodes, but not Peyer's patches, of recipient animals (47). 
Other investigators have described a monoclonal antibody specific for a lympho- 1064  vIP RECEPTORS AND THE  IN  VIVO LOCALIZATION OF T  CELLS 
cyte surface molecule of murine B  and  T  cells (48).  Pretreatment of mouse 
lymphocytes with  this  antibody  blocked  the  binding  of the  lymphocytes to 
peripheral lymph node HEV in vitro and inhibited the accumulation of the cells 
in  peripheral  lymph  nodes  in  vivo,  but  had  no  effect on  the  interaction  of 
iymphocytes with  Peyer's patches,  either in  vitro or  in  vivo (48).  While  it  is 
possible that the peptide-treated cells investigated here had experienced concur- 
rent  alterations  in  both  their  VIP  receptors  and  other  specific  cell  surface 
components influencing their migration, the most direct hypothesis by which to 
interpret  the  treatment-dependent decreases in  VIP  receptor expression and 
migration into MLN and Peyer's patches is that the presence of VIP receptors 
contributes to  the way in  which T  cells interact with the specialized vascular 
endothelium of those organs. 
The spleen, in contrast to lymph nodes and Peyer's patches, does not contain 
recognizable HEV, and alteration of the surface of lymphocytes with, for exam- 
ple,  trypsin has little or no effect on the entry of lymphocytes into the spleen 
(49, 50). Trypsin treatment decreases the interaction of lymphocytes with HEV 
in vitro (51), however, and their accumulation in HEV-containing organs in vivo 
(49, 50). The finding that altered VIP receptor expression of T  cells is associated 
with  changes in  the  early localization  of those  cells  in  mesenteric node and 
Peyer's patches without allied changes in the localization in the spleen, therefore, 
is consistent with the notion that the VIP receptors may play a permissive role 
in the interaction of T  cells with HEV in these organs. 
The precise means by which T  cell receptors for VIP could affect the inter- 
action  of T  cells  with  HEV  is  not  known.  VIPergic nerve fibers have  been 
identified in close proximity to small blood vessels in a number of tissues (52- 
55).  It is possible that local release of VIP from VIPergic nerve endings may 
occur near HEV or within other elements of the microvasculature of mesenteric 
nodes and Peyer's patches. Occupancy of  their VI P receptors by the neuropeptide 
may alter the state of activation of the T  cells or facilitate the presentation of 
other surface components on the T  cells mediating their interaction with HEV. 
These considerations emphasize how  little is  known about  the innervation, 
particularly the peptidergic innervation, of lymphoid tissues,  but  the concept 
that VIP receptors on T  cells influence the interaction of these cells with HEV, 
and thus influence the migration of T  cells, is consistent with other observations. 
First,  the number of VIP receptors expressed by thymocytes is low compared 
with T  cells from secondary lymphoid organs (18).  It has been found that the 
binding of thymocytes to HEV in vitro is much lower than that displayed by T 
cells from lymph nodes (56), and thymocytes localize less well in lymph nodes 
and Peyer's patches than do T  cells from secondary lymphoid tissues (57,  58). 
Second, T  cells from different secondary lymphoid organs appear to have similar 
migratory properties (59,  60), as well as similar HEV-binding capabilities (44) 
and the expression of VIP-binding sites by T  cells is uniform throughout the 
secondary lymphoid organs (18). 
The finding that no difference in the tissue localization of the pretreated cell 
populations was apparent at 18 h after cell transfer may reflect the superposition 
of other processes that affect the retention and redistribution of lymphocytes at 
later times. Alternatively, the altered receptor properties induced during the in OTTAWAY  1065 
vitro  incubation  may  have  reverted  after  prolonged  periods  in  vivo.  Further 
studies will  be required  to determine whether the induced receptor alterations 
are reversible in vivo. 
It is not known to what extent these experimental animal  studies model the 
behavior of T  cells in humans,  but human  peripheral  blood T  cells have been 
shown to have specific receptors for VIP (16). If local interactions with VIP can 
affect the migration of human T  cells, this could have important pathological as 
well as physiological implications. For example, abnormalities of VIP-containing 
nerves have  been  identified  in  the  mucosa and  submucosa of the  intestine  of 
patients with Crohn's disease as well as in the vicinity of granulomas of Crohn's 
affected bowel (61).  Disruption  of the local interaction  of VIP with  T  cells in 
these regions  may contribute,  therefore,  to the  lymphocytic infiltrate  and  the 
pathophysiology of this disease. 
Summary 
The capacity of T  lymphocytes exposed in vitro to the neuropeptide vasoactive 
intestinal peptide (VIP) to bind VIP in vitro and to migrate to different tissues 
in vivo has been studied. VIP treatment of T  cells resulted in a time- and dose- 
dependent loss of the ability of T  cells to specifically bind radioiodinated  VIP. 
Altered binding was due to a decrease in the expression of cellular receptors for 
VIP on the treated cells rather than an alteration  in the affinity of the cells for 
the neuropeptide. Alteration of VIP receptor expression was not associated with 
a  change  in  the  expression  of Thy-1,  Lyt-1,  or  Lyt-2 surface  markers  by the 
treated  cells.  VIP  treatment  of T  cells in  vitro  resulted,  however,  in  a  dose- 
dependent decrease in  the ability of the  treated cells to localize in  mesenteric 
lymph nodes (MLN) and Peyer's patches of recipient animals at early times after 
cell transfer, and this was due to a selective decrease in the rate of accumulation 
of the treated cells in these tissues. There was no alteration  in the distribution 
of VIP-treated  cells in  the  blood, spleen,  liver,  or other  major  organs  of the 
recipient animals.  It is concluded that the presence of VIP receptors on T  cells 
facilitates the entry of T  cells into  MLN and  Peyer's patches in vivo, and it is 
proposed that  this effect is mediated by T  cell-VIP interactions  in the vicinity 
of the specialized endothelium of those tissues. 
I thank Dr. G. R. Greenberg for providing the radioiodinated VIP used in these studies. 
I also thank Dr. G. A. Levy for a critical reading of the manuscript. 
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